. . "Gallium nitrate is not metabolized either by the liver or the kidney and appears to be significantly excreted via the kidney."@en . . . "13494-90-1"@en . . . "investigational"@en . . . . . . . . . "For the treatment of hypercalcemia. Also intended for the treatment of non-hodgkin's lymphoma."@en . "approved"@en . "# Yang M, Kroft SH, Chitambar CR: Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther. 2007 Feb;6(2):633-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17308060 # Leyland-Jones B: Treating cancer-related hypercalcemia with gallium nitrate. J Support Oncol. 2004 Nov-Dec;2(6):509-16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15605917 # Chitambar CR: Apoptotic mechanisms of gallium nitrate: basic and clinical investigations. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):39-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15651176 # Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr: Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J. 2006 Jan-Feb;12(1):47-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16613662"@en . . . . . . . "Humans and other mammals"@en . . . . . . . . . . "* 0.15 L/hr/kg [cancer patients receiving daily infusion of gallium nitrate at a dose of 200 mg/m2 for 5 or 7 days]"@en . . . . . . "Gallium nitrate is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. This condition may occur when individuals develop various types of cancer. Gallium nitrate is also known by the common brand name Ganite."@en . "Gallium nitrate"@en . "Alpha: 1 hour. Beta: 24 hours, but lengthens to 72 to 115 hours with prolonged intravenous infusion."@en . "Gallium nitrate is believed to exert a hypocalcemic effect by inhibiting calcium resorption from bone. Gallium nitrate localizes preferentially where bone resorption and remodeling is occurring, and inhibits osteoclast activity. Inhibition of resorption may occur via a reduction in increased bone turnover. It seems to enhance hydroxyapatite function, inhibit osteocalcin, and inhibit the vacuolar ATPase on the osteoclast ruffled membrane. All these aid in the reduction of bone resorption."@en .